Receptor-targeted scintigraphy using radiolabeled
somatostatin analogs such as octreotate is being used with great success to demonstrate the in vivo presence of
somatostatin receptors on various
tumors. A new and promising application for these analogs is
radionuclide therapy.
Radionuclides suitable for this application include the Auger electron-emitter (111)In and the beta-emitters (90)Y (high energy) and (177)Lu (low energy). We investigated [
DOTA(0),
Tyr(3)]octreotate, labeled with the
lanthanide (177)Lu, in biodistribution and
radionuclide therapy experiments using male Lewis rats bearing the
somatostatin receptor-positive rat CA20948 pancreatic
tumor. Biodistribution studies in Lewis rats showed the highest uptake in the rat pancreatic CA20948
tumor and sst(2)-positive organs, which include the adrenals, pituitary and pancreas, of [(177)Lu-
DOTA(0),
Tyr(3)]octreotate in comparison with (88)Y- and (111)In-labeled analogs. Kidney uptake of [(177)Lu-
DOTA(0),
Tyr(3)]octreotate could be reduced by approximately 40% by co-injection of 400 mg/kg D-
lysine. In
radionuclide therapy studies, a 100% cure rate was achieved in the groups of rats bearing small (< or =1 cm(2)) CA20948
tumors after 2 doses of 277.5 MBq or after a single dose of 555 MBq [(177)Lu-
DOTA(0),
Tyr(3)]octreotate. A cure rate of 75% was achieved after a single administration of 277.5 MBq. In rats bearing larger (> or =1 cm(2))
tumors, 40% and 50% cure rates were achieved in the groups that received 1 or 2 277.5 MBq
injections of [(177)Lu-
DOTA(0),
Tyr(3)]octreotate, respectively. After
therapy with [(177)Lu-
DOTA(0),
Tyr(3)]octreotide in rats bearing small
tumors, these data were 40% cure after 1 injection with 277.5 MBq and 60% cure after 2 repeated
injections. In conclusion, [(177)Lu-
DOTA(0),
Tyr(3)]octreotate has demonstrated excellent results in
radionuclide therapy studies in rats, especially in animals bearing smaller
tumors. This candidate molecule shows great promise for
radionuclide therapy in patients with sst(2)-expressing
tumors.